AEPGX | RIVIX | AEPGX / RIVIX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 41 years | 5 years | - |
Gain YTD | 6.664 | 7.554 | 88% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 250 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 131B | 2.1B | 6,235% |
Annual Yield % from dividends | 1.49 | 1.07 | 140% |
Returns for 1 year | 1.63 | 5.27 | 31% |
Returns for 3 years | 1.84 | 14.16 | 13% |
Returns for 5 years | 8.34 | 24.44 | 34% |
Returns for 10 years | 21.17 | N/A | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
JFNCX | 60.13 | -0.44 | -0.73% |
Janus Henderson Global Life Sciences C | |||
NQGCX | 36.19 | -0.37 | -1.01% |
Nuveen Global Equity Income C | |||
ETAHX | 34.23 | -0.36 | -1.04% |
Eventide Healthcare & Life Sciences A | |||
REPSX | 39.61 | -0.49 | -1.22% |
ProFunds Real Estate UltraSector Svc | |||
GSLAX | 16.33 | -0.24 | -1.45% |
Goldman Sachs Large Cap Value A |